Idexx Laboratories, Inc (NASDAQ: IDXX) kicked off on Tuesday, up 0.69% from the previous trading day, before settling in for the closing price of $433.99. Over the past 52 weeks, IDXX has traded in a range of $356.14-$548.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 10.23% over the last five years. While this was happening, its average annual earnings per share was recorded 12.29%. With a float of $80.20 million, this company’s outstanding shares have now reached $81.60 million.
The firm has a total of 11000 workers. Let’s measure their productivity. In terms of profitability, gross margin is 61.08%, operating margin of 28.99%, and the pretax margin is 28.48%.
Idexx Laboratories, Inc (IDXX) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Diagnostics & Research Industry. The insider ownership of Idexx Laboratories, Inc is 1.03%, while institutional ownership is 90.94%. The most recent insider transaction that took place on Feb 10 ’25, was worth 4,618,862. In this transaction Executive Vice President of this company sold 9,986 shares at a rate of $462.53, taking the stock ownership to the 8,176 shares. Before that another transaction happened on Feb 10 ’25, when Company’s Officer proposed sale 9,966 for $463.46, making the entire transaction worth $4,618,863.
Idexx Laboratories, Inc (IDXX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 3.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 12.29% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.89% during the next five years compared to 16.90% growth over the previous five years of trading.
Idexx Laboratories, Inc (NASDAQ: IDXX) Trading Performance Indicators
Take a look at Idexx Laboratories, Inc’s (IDXX) current performance indicators. Last quarter, stock had a quick ratio of 0.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.09. Likewise, its price to free cash flow for the trailing twelve months is 43.82.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 10.67, a number that is poised to hit 2.85 in the next quarter and is forecasted to reach 13.50 in one year’s time.
Technical Analysis of Idexx Laboratories, Inc (IDXX)
Analysing the last 5-days average volume posted by the [Idexx Laboratories, Inc, IDXX], we can find that recorded value of 0.88 million was better than the volume posted last year of 0.81 million. As of the previous 9 days, the stock’s Stochastic %D was 87.21%. Additionally, its Average True Range was 14.58.
During the past 100 days, Idexx Laboratories, Inc’s (IDXX) raw stochastic average was set at 68.20%, which indicates a significant decrease from 94.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.81% in the past 14 days, which was higher than the 36.22% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $422.93, while its 200-day Moving Average is $447.76. Now, the first resistance to watch is $440.95. This is followed by the second major resistance level at $444.93. The third major resistance level sits at $450.85. If the price goes on to break the first support level at $431.05, it is likely to go to the next support level at $425.13. Should the price break the second support level, the third support level stands at $421.15.
Idexx Laboratories, Inc (NASDAQ: IDXX) Key Stats
The company with the Market Capitalisation of 35.41 billion has total of 81,039K Shares Outstanding. Its annual sales at the moment are 3,898 M in contrast with the sum of 887,870 K annual income. Company’s last quarter sales were recorded 954,290 K and last quarter income was 216,150 K.
